Rule 8.3- CeNeS Pharmaceutica
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
1. KEY INFORMATION
|
Name of person dealing (Note 1) |
GlaxoSmithKline plc and its subsidiaries |
|
Company dealt in |
CeNeS Pharmaceuticals plc |
|
Class of relevant security to which the dealings being disclosed relate (Note 2) |
Ordinary 30p shares |
|
Date of dealing |
29 May 2008 |
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
|
Long |
Short |
|
|
Number (%) |
Number (%) |
|
(1) Relevant securities |
563,568 2.56% |
|
|
(2) Derivatives (other than options) |
|
|
|
(3) Options and agreements to purchase/sell |
|
|
|
Total |
563,568 2.56% |
|
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
|
Class of relevant security: |
Long |
Short |
|
|
Number (%) |
Number (%) |
|
(1) Relevant securities |
|
|
|
(2) Derivatives (other than options) |
|
|
|
(3) Options and agreements to purchase/sell |
|
|
|
Total |
|
|
(c) Rights to subscribe (Note 3)
|
Class of relevant security: |
Details |
|
|
|
3. DEALINGS (Note 4)
(a) Purchases and sales
|
Purchase/sale |
Number of securities |
Price per unit (Note 5) |
|
|
|
|
(b) Derivatives transactions (other than options)
|
Product name, e.g. CFD |
Long/short (Note 6) |
Number of securities (Note 7) |
Price per unit (Note 5) |
|
|
|
|
|
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
|
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
|
(ii) Exercising
|
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 5) |
|
|
|
|
(d) Other dealings (including new securities) (Note 4)
|
Nature of transaction (Note 8) |
Details |
Price per unit (if applicable) (Note 5) |
|
Issue of shares |
120,752 Ordinary shares of 30p each issued pursuant to a share exchange agreement dated 21 November 2003 between CeNeS Pharmaceuticals plc and GlaxoSmithKline. |
Not Applicable |
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
|
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
|
|
Is a Supplemental Form 8 attached? (Note 9) NO
|
Date of disclosure |
29 May 2008 |
|
Contact name |
Victoria Whyte |
|
Telephone number |
020 8047 5000 |
|
If a connected EFM, name of offeree/offeror with which connected |
|
|
If a connected EFM, state nature of connection (Note 10) |
|
Notes
The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk
Latest directors dealings
- 23 hours ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund